Linda Frisk, PharmD: Biosimilars and Cost Reduction

April 2, 2018

Linda Frisk, PharmD, of Arizona Oncology, discusses biosimilars and cost savings.

Transcript:

What is your understanding of the use of biosimilars at your practice?

Well there’s not too many biosimilars out right now. I do believe that there is a cost advantage to them, and I haven’t seen any difference in efficacy with the 1 that we’re currently using now. I am very much looking forward to that; I think that it will reduce cost and that’s what we need to do.